London

David Wilson

David is Chairman and founding partner of WG Partners and has over 30 years of experience in the City. Previously David was CEO of Piper Jaffray Ltd, where he also served as Global Chairman of Healthcare and on the Group Leadership Team. David has held senior positions at ING Barings as Joint Head of UK Investment Banking Group, Deutsche Bank as Head of Small Companies Corporate Finance and UBS as Head of Small Companies Corporate Broking. David currently serves as non-executive Director of Neuphoria Therapeutics Inc. and was previously Senior Independent Director of Optos plc prior to its successful sale to Nikon Corporation for c.$400m as well as a non-executive director of BerGenBio AS.

Nigel Barnes

Nigel is a Senior Partner at WG Partners. He has over 40 years of experience working in the City, having been a Director of Pharmaceutical research at ABN AMRO, FVP Merrill Lynch Healthcare Equity Research and a Partner at Sudbrook Associates, a healthcare corporate advisory business. He holds a PhD in pharmacology, and, before working in the City, worked in the Pharmaceutical industry for ICI (now AstraZeneca) and Glaxo. Nigel has played an active role in numerous leading corporate transactions, including several significant European sector mergers, IPOs, and capital raises.

Claes Spång

Claes has over 25 years of investment banking experience. Prior to joining WG Partners Claes was Director of Corporate Finance at Singer Capital Markets and before that he worked at Landsbanki and Bridgewell having joined from Baird in 2005. Claes has substantial experience in actively managing and executing both domestic and international corporate transactions including IPOs, capital raises and M&A both for public and private companies. Prior to joining the City Claes was a sergeant in the Swedish armed forces.

Olga Holme

Olga is a founding Partner at WG Partners, bringing over 28 years of extensive experience in investment banking and equity capital markets within the City of London. Olga has specialised in corporate access, trading support, and institutional client relations. Prior to WG Partners, she served as Associate Vice President of Corporate Access within the Corporate Broking and Equity Capital Markets (ECM) division at Piper Jaffray. Her foundational expertise in global markets was established at Nomura International, where she managed comprehensive trade support operations across both Emerging Markets and UK Equities.

Erland Sternby

Erland is a healthcare specialist salesman with over 25 years in the City of London, covering BioPharma and Med-Tech for investors globally. He has been top-rated in specialist sales both individually and as part of the #1 pharma team at Dresdner Kleinwort. In recent years his focus has been corporate transactions. Prior to specialist equity sales, Erland started his career as a medical doctor in Sweden. He then joined Astra in clinical research. After a business BSc and an international MBA in France, he worked for biotech companies in marketing and business development in Europe. In 1997, he moved into finance as a BioPharma analyst with Alfred Berg in Stockholm, before moving to London in 2000.

Robin Stürken

Robin has more than 25 years of financial advisory experience, primarily in private and public M&A transactions and growth capital financings as well as strategic advice. Prior to joining WG Partners in 2021, Robin was with Healthcare & Life Sciences sector dedicated financial advisory boutique Northridge Advisory for eight years, actively originating and executing numerous transactions in the UK and internationally. Prior to joining Northridge, Robin was with M&A advisory boutique Hawkpoint Partners (now part of Canaccord Genuity), also for eight years. He began his investment banking career in 1998 in the corporate finance & advisory department of HSBC Investment Bank in London. Robin is a German national and holds a finance degree from London Business School.

Parthiv Patel

Parthiv has over 12 years of specialist experience providing M&A, capital raising and strategic advisory services across the AI-enabled healthcare, diagnostics, and life sciences markets. He brings a rare combination of advisory and principal-side expertise, having held Corporate Development roles at Owkin AI — where he led the carve-out and fundraising of the digital pathology diagnostics division (now Waiv) — and nference, an AI drug discovery platform leveraging real-world evidence from over 22 million patients across leading US health systems, on venture creation. Prior to this, Parthiv held senior roles at Deloitte and Raymond James in London, executing cross-border healthcare transactions to private equity. Parthiv is a Chartered Accountant and member of the ICAEW.

Alice Whelan

Alice worked as a Program Associate at Complement Therapeutics, a UK-based biotechnology company developing gene therapies for dry age-related macular degeneration, contributing to program delivery and strategy. She has also gained global experience with various healthcare focused hedge funds and VC, supporting scientific diligence, market analysis, and company assessment. Alice holds a BSc in Biochemistry and MSc in Biotechnology from Imperial College London.

Sydney

Anthony Brown

Anthony entered the financial services sector on the buyside at Royal Sun Alliance investment management after completing a Ph.D at the Institute of Cancer Research in London. RSAIM became part of F&C via two mergers and during this time Anthony won the Thomson Extel Award as best buyside Biotech analyst of 2005. In 2007 Anthony joined the Abu Dhabi Investment Authority, one of the world’s largest sovereign wealth funds, in London. In 2011 Anthony left financial services to join AstraZeneca working directly for the CFO Simon Lowth before joining the Investor Relations department in 2013. Anthony emigrated to Australia in December and joined WG Partners in early 2015.

Industry Advisor

Julian Chick

Dr Julian Chick has over 25 years of C-suite and board experience in healthcare and life sciences as well as five years in investment banking and has also been a healthcare analyst for private equity investors and venture capitalists. Over the past 20 years Julian has been involved in numerous public and private company capital raisings, M&A transactions, company restructurings, business development and licensing transactions and corporate strategic planning. Julian has a PhD in Physiology.

London

WG Partners
85 Gresham Street
London
EC2V 7NQ

Sydney

WG Partners Pty Ltd.
Level 2 Unit 204
111 Harrington Street
Sydney
NSW 2000